Almac Diagnostic Services We are a precision medicine company specialising in biomarker driven clinical trials. Our global CLIA and CAP accredited laboratories cover UK, Europe, USA and APAC regions. Our cores services: * Multi-Omic Services: We offer a range of genomic & proteomic platform and chemistry options, alongside expert data sciences support & a specialty central lab service. * Clinical Biomarker & CDx Development: Custom Clinical Biomarker & CDx development, validation & delivery service from our CLIA & CAP accredited laboratories in USA, Europe and APAC. * Clinical Testing: Global clinical trial testing service from our clinical laboratories, including a menu of platforms & assays and an integrated specimen collection & logistics service. Find Out More www.almacgroup.com/diagnostics | The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Operating from state-of-the-art facilities in the US, Europe, and the UK, Almac Pharma Services is a FDA, HPRA, and MHRA approved CDMO partnering with global pharmaceutical and biotechnology industries. We have over 50 years’ experience in providing a comprehensive range of tailored solutions. Almac possesses a wealth of technical expertise to support the delivery of your complex projects. Our scientists can develop your clinical candidate into an optimum formulation, and solid manufacture oral dose products for all stages of clinical trials. Almac’s integrated pharmaceutical development solutions are tailored to meet your needs. We specialise in the manufacture & primary packaging of solid, oral dosage forms (Tablets, Capsules and Powders). As well as customised secondary packaging for all drug products including ultra-low temperature drug products. Almac works in close partnership with our clients offering unique solutions designed to support the efficient and successful development, and commercialisation of new treatment options. | Operating from state-of-the-art facilities in the US, Europe, and the UK, Almac Pharma Services is a FDA, HPRA, and MHRA approved CDMO partnering with global pharmaceutical and biotechnology industries. We have over 50 years’ experience in providing a comprehensive range of tailored solutions. Providing end-to-end integrated solutions to bring your drug product from development through to commercialisation from a single source. We work with clients to provide pharmaceutical development, manufacturing, product launch, and packaging solutions to fit their unique needs. Our team of experts can support the development of fit-for-purpose formulation for First-in-Human trials, to developing a more robust formulations scaling up for late phase trials, and ultimately commercialisation. Supporting key development and manufacture areas such as paediatrics, potent and highly potent products. We provide primary and secondary packaging for all drug products including ultra-low temperature drug products and specialised kit assembly. Almac was one of the 1st EU CDMOs to support gene therapy product launches, and currently supports 25% of EU approved/pre-registration Gene Therapy solutions. We provide end-to-end management of drug product supply, including distribution, packaging design, and support initial and ongoing global product launch. We provide unique, tailormade solutions designed to support the efficient and successful development, and commercialisation of new treatment options. Partnering with our clients to provide flexible, stable, ongoing supply to meet their product pipeline needs. | The Almac Group is a global leader in providing a range of expert services and support across the drug development lifecycle. A privately owned organisation, under the McClay Foundation, Almac has grown organically over the past five decades, now employing over 7,500 highly skilled individuals across 18 locations in Europe, the US and Asia. Almac Group is comprised of 5 Business Units: • Almac Diagnostic Services • Almac Sciences • Almac Pharma Services • Almac Clinical Services • Almac Clinical Technologies Each Business Unit offers specialist and dedicated solutions at each phase of the product lifecycle providing the ability to select single or multiple, integrated solutions to meet your unique needs. Our unique combination of inspirational people, exceptional innovation and outstanding quality, enables us to provide tailored solutions for your specific requirements – either on a single, standalone project or on a long-term basis as your strategic partner. About Almac Pharma Services: With over 55 years’ experience, Almac Pharma Services is an established, reliable and world leading outsourcing partner to the global pharmaceutical and biotechnology industry. Employing over 1,800 highly skilled individuals across 4 locations in Europe and the US, we provide a range of tailored, quality-led and timely solutions from early and late phase pharmaceutical development, clinical and commercial drug product manufacture, product launch through to commercial packaging and global distribution. Currently supporting client portfolios across more than 70 countries, our fully integrated, end-to-end solutions are tailored to meet the needs of your unique products, and, ultimately, your patients. Pharmaceutical Development Solutions: Spanning both early and late phase development, our teams of expert scientists possess a wealth of experience in developing clinical candidates into optimal formulations and manufacturing high-quality oral dose products for all phases of clinical trials. Operating both non-GMP and GMP facilities we have complementary equipment trains and integrated technical teams to facilitate technology transfer providing a seamless transition between formulation and process development, and clinical trial material manufacturing. Through a range of flexible and fully tailored unit operations including blending, roller compaction, high shear granulation, encapsulation (including Xcelodose) micro encapsulation and fluid bed processing, we offer the following oral dose formulations with batch sizes ranging from grams to tons: • API / powder in hard gelatin capsules or bottles, including micro-dosing • Formulated blends in hard gelatin capsules or bottles • Tablets (coated) • Mini-tablets • Granules • Beads/pellets • Non-sterile liquid in capsules or bottles • Immediate and modified release • Fixed dose combination products • Potent and highly potent products (OEL as low as 0.05 ug/m3/8 hours) • Specialist paediatric drug development expertise Analytical Solutions: We employ over 700 highly skilled analysts working in state-of-the-art, fully certified GMP laboratories across Europe and the US with significant experience in the analysis of both small and large molecules. We support drug substance (API) and drug product (finished product) analytics across all phases of clinical development through to commercial release. We offer a range of tailored services including: • Method development • Method validation • Method transfer • Stability programmes • Release analysis: all lifecycle stages • Spectroscopy services • Investigational analysis • Reference standard management • Microbiological testing • Physical sciences • Bio-pharmaceutical testing • Analytical support for clinical trial supplies Commercial Manufacture Solutions: Scaling up from our oral dose development assets and expertise through registration and launch into commercial supply, or transferring existing commercial products, we support your commercial manufacturing needs with flexibility and expertise. With blend sizes from 10kgs up to 2.5 tons, our range of state-of-the-art processing equipment is designed to enable scalability to the batch size requirements of your product for a range of presentations including: • Tablets • Mini-tablets • Capsules • Powders • Granules • Beads/pellets • Non-sterile liquids • Potent and highly potent products (OEL as low as 0.05 ug/m3/8 hours) • Specialist paediatric drug manufacturing expertise Commercial Packaging Solutions: Our high and low throughput operations provide the flexibility and efficiency necessary to meet your ongoing and fluctuating demand. Our commercial facilities in Europe and the US, combined with our local expertise offers flexible, quality-led commercial pharmaceutical packaging solutions tailored to meet your specific needs. Our range of primary packaging solutions include: • Tablets • Mini-tablets • Capsules • Powders • Granules • Non-sterile liquid • Our secondary packaging, labelling and assembly capabilities include: • Bottles Vials / ampoules • Pre-filled syringes • Wallets / blister cards • Auto-injectors • Cartons • Sachets • Stick packs • Offline blister printing Innovative, specialist packaging solutions including: • Specialist paediatric drug packaging expertise • Expert cell and gene therapy (ATMP) Ultra Low Temperature (ULT) solutions (-20° to -80°) • Complex medical kit assembly solutions via our unique, custom built semi-automated packaging technology Support Solutions: We provide a wide range of tailored support and consultancy services to help guide you through every aspect of your unique development and commercialisation journey. Find out more – www.almacgroup.com
Allsino Pharmaceutical Co., Ltd.
Allsino pharmaceutical Co., Ltd. Your Premier Partner in Small Molecule & Peptide CDMO Services Company Overview Founded in May 2004, Allsino Biopharmaceutical Co., Ltd.is a wholly-owned subsidiary of Sinopep-Allsino Biopharmaceutical Co., Ltd. (Stock Code: 688076), a publicly traded company on the Shanghai Stock Exchange’s STAR Market . Headquartered in Hangzhou, China, Allsino is a globally recognized Contract Development and Manufacturing Organization (CDMO), specializing in the research, development, and production of innovative small molecule drugs, advanced pharmaceutical intermediates, and peptide fragments. With a steadfast commitment to quality and innovation, Allsino serves as a critical bridge between early-stage drug discovery and commercial manufacturing, helping partners accelerate timelines and reduce risks. Strategic Locations: R&D and GMP Manufacturing Allsino operates an integrated Hangzhou R&D + Jiande Manufacturing” dual-site model to ensure seamless technology transfer and scalable production. R&D Center (Hangzhou, Zhejiang): Location: Yuhang District, Hangzhou. Status: Recognized as a Provincial Enterprise Research Institute by the Zhejiang Provincial Government . Capabilities: Houses over 100 scientists, including Ph.D. and Master’s level chemists. The center focuses on core technologies such as small molecule catalysis, continuous flow chemistry, and solid-phase peptide synthesis. – GMP Commercial Production Base (Jiande, Zhejiang): – Location:Jiande City, Hangzhou. – Scale: Spanning 60,000+ square meters(approx. 146 Mu) . – Certification: Operates under strict cGMP standards, compliant with US FDA, EDQM, and NMPA regulations . In 2023, the facility successfully passed the NMPA GMP evaluation for APIs . Core Business & Technical Expertise Allsino is an innovation-driven entity that has successfully initiated and developed over 300 projects across various therapeutic areas, including oncology, central nervous system (CNS) disorders, and metabolic diseases (including GLP-1 analogs for diabetes and obesity) . Key Services: Process Development & Scale-up: From laboratory synthesis to multi-ton commercial production. – Custom Synthesis: Advanced intermediates, Registered Starting Materials (RSMs), and GMP-grade Active Pharmaceutical Ingredients (APIs) . Peptide CDMO Services:Specializing in peptide fragments and oligonucleotides. Commercial Manufacturing: Supporting NDA filings and commercial launch. Quality & Global Recognition Allsino’s commitment to pharmaceutical excellence is validated by its long-standing partnerships with top-tier global pharmaceutical companies. Global Partnerships:The company has established long-term technical collaborations with Fortune 500 pharmaceutical companies such as ****** . Industry Award: In 2022, Allsino was honored with the “SK Pharmteco Preferred Partner Award” at CPhI Frankfurt. Notably, Allsino was the only Chinese company selected among nearly 100 global suppliers to receive this distinction . Intellectual Property: Holds over 20 patents (including inventions and utility models) . Certifications – US FDA (cGMP) – NMPA (China GMP) – ISO 9001, ISO 14001, ISO 45001 Workforce & Assets Employees:500+ , including a highly educated technical team of 240+ professionals (6 Ph.D.s, 16 Master’s degrees) . Annual R&D Investment: Consistently exceeds 10% of revenue, ensuring continuous technological innovation . Contact Information Website:[www.allsino.com](http://www.allsino.com) R&D Center Address: 4F, Building 1, No. 39 Keji Avenue, Yuhang District, Hangzhou, Zhejiang, China (Postal Code: 311121) Manufacturing Base Address:No. 18 Fenghe Road, Xiaya Town, Jiande City, Hangzhou, Zhejiang, China (Postal Code: 311606) Phone: +86-571-89961929 / +86-571-88180350 Email (Sales): sales@allsino.com Allsino pharmaceutical Co., Ltd.—Bridging Innovation from Lab to Market.
Agilent Advanced Therapeutics, fka BIOVECTRA
Agilent Advanced Therapeutics is Agilent’s contract development and manufacturing organization (CDMO), bringing together BIOVECTRA’s proven expertise in biologics fermentation, complex chemistry, highly potent APIs, and bioreagents, with Agilent’s Nucleic Acid Solutions Division capabilities in oligonucleotides and advanced nucleic acid manufacturing. Together, these complementary strengths create a unified CDMO partner supporting advanced therapeutics from development through commercial supply. Combining white-glove service, deep scientific expertise, and long-term investment, Agilent Advanced Therapeutics delivers customized end-to-end solutions designed around each client’s needs. Backed by rigorous, data-driven processes and Agilent’s global quality systems, our scientists work alongside yours to help move programs forward with confidence. Invested in science, invested in your success.
Afton Scientific
Afton Scientific is a highly-experienced cGMP CMO specializing in sterile injectables. We can Formulate, Aseptically Fill, Label, and Package your small-batch parenterals. Our customers include major global pharmaceutical companies and emerging biotechs. Sterile manufacturing services offered Clinical Trial and Commercial Drug Products Both Small and Large Molecule Inspected by Both CDER and CBER International Standards – FDA, PMDA, MHRA, and EMA Terminal Sterilization Engineering and Formulation Scale-Up Commercial Batch Record Development Technology Transfer Analytical Support Regulatory Filing Assistance Label/Pack/Serialization Our flexibility allows us to get client projects on the schedule as quickly as possible and maintain robust regulatory compliance. Quality assurance and in-house analytical services allow us control over product release timelines to ensure that products hit the market or clinic on time. Our facilities can handle vial sizes from 2mL – 100mL and batch sizes from thousands to tens of thousands making us an ideal fit for small-run commercial drugs and clinical trial materials. | Afton Scientific is a U.S.-based CDMO specializing in aseptic fill-finish for biologics and small molecule products, with more than 20 years of manufacturing excellence. We are early technology adopters, and our newest capability reflects that commitment: a state-of-the-art, Annex 1–compliant isolator-based filling line supporting vials, syringes, and cartridges, purpose-built to meet the highest standards in sterile manufacturing and position our partners for global market access. What sets Afton apart is how we work. Our clients have direct access to experienced leadership and technical teams from day one. We embed ourselves in your program, bring deep technical expertise, and stay close through every stage of development and manufacturing. With available capacity today, a growing facility footprint, and a culture built around solving hard problems, Afton is ready to support your program now and as it scales.
Aenova
The Aenova Group is a leading global contract manufacturer and development services provider for the pharmaceutical and healthcare industry. Our services include end-to-end manufacturing and development of all dosage forms and potency levels (ranging from nutraceuticals to high-potents) out of 15 sites in Europe and the US. Aenova can offer sterile compounding and filling of liquids in Pre-Filled Syringes, either aseptically filled or terminally sterilized, on filling lines equipped with barrier technology (RABS or Isolators). Aenova is the ideal partner for development and production of virtually all types of solid dosage forms and APIs up to OEB 5. Aenova has more than 35 years of experience in the formulation and analytical development and production of soft gelatin capsules. Our production facilities are equipped with state-of-the-art equipment to process any formulation and any capsule design, color and size. With development and manufacturing capacities including high potent active pharmaceutical drugs at our Center of Excellence in Kirchberg/Switzerland also with the ability to manufacture with high potent active pharmaceutical ingredients which can be handled within adequate equipment like gloveboxes for OEB 5 level and closed process tank systems. With our comprehensive know-how, many years of experience, well-trained staff of 4,200 employess, innovative technologies and highest quality standards we are a reliable, long-term partner to pharmaceutical and consumer health care customers around the world, both in the human and veterinary healthcare market. | Aenova is one of the leading contract development and manufacturing organizations (CDMOs) in the global pharmaceutical supply chain. They provide services covering the entire value chain from development to commercialization for all common product groups and dosage forms (solid, semisolid, sterile, and nonsterile liquid). The company supplies drugs up to OEB 5 and food supplements for both human and veterinary use. They are also able to handle differentiated technologies such as HPAPI containment, low-dose, modified release formulations, organic granulation, particulate systems, lipid-based formulas, HME or spray drying for poorly soluble compounds. Aenova offers customers a wide-ranging service portfolio and challenges itself to expedite time to market and facilitate the drug development journey. The one-stop-shop experience stretches from early phase formulation and product development to the purchase of raw materials, analytics, regulatory support, small and full-scale production, market release through to packaging and logistics. Aenova develops, produces and packages across a network of 14 sites in the US, Germany, Switzerland, Italy, Ireland, and Romania, with headquarters near Munich, Germany. The manufacturing sites are complemented by seven specialized Development Competence Centers for various technologies and dosage forms that support clients with tailormade solutions. A highly motivated international team of nearly 4,000 employees from over 50 nations contributes to the group’s strong, long-lasting customer partnerships and continuous development. Excellence & Reliability are anchored in the company culture as core values, benefiting customers in the shape of ample capacities, back-up sourcing within the group, and continued capital investment in capacities and capabilities. In line with a “Customers & Patients first” mentality, a dedicated Business Management team is in place to provide personalized customer service, address needs and solve potential issues efficiently. Aenova’s client base consists of most of the leading global players in pharmaceuticals, consumer healthcare, veterinary health and dietary supplements, as well as many small and mid-size pharma and biotech companies. Surveys show that the majority of the group’s clients consider Aenova their preferred supplier and report a strong overall satisfaction in working with the group. | Aenova Group – CDMO Value Creation Across the Entire Product Lifecycle Aenova is one of the leading contract development and manufacturing organizations (CDMOs) in the global pharmaceutical supply chain. They provide services covering the entire value chain from development to commercialization for all common product groups and dosage forms (solid, semisolid, sterile, and nonsterile liquid). The company supplies drugs up to OEB 5 and food supplements for both human and veterinary use. They are also able to handle differentiated technologies such as HPAPI containment, low-dose, modified release formulations, organic granulation, particulate systems, lipid-based formulas, HME or spray drying for poorly soluble compounds. Aenova offers customers a wide-ranging service portfolio and challenges itself to expedite time to market and facilitate the drug development journey. The one-stop-shop experience stretches from early phase formulation and product development to the purchase of raw materials, analytics, regulatory support, small and full-scale production, market release through to packaging and logistics. Aenova develops, produces and packages across a network of 14 sites in the US, Germany, Switzerland, Italy, Ireland, and Romania, with headquarters near Munich, Germany. The manufacturing sites are complemented by seven specialized Development Competence Centers for various technologies and dosage forms that support clients with tailormade solutions.
Advanced Technology International
ATI, a nonprofit based in Summerville, S.C., builds and manages collaborations that conduct research and development of new technologies to solve our nation’s most pressing challenges. Fueled by a community of experts from industry, academia, and government, ATI uses the power of collaboration to help the federal government quickly acquire novel technologies. ATI manages both Other Transaction Agreement (OTA)-based and Federal Acquisitions Regulations (FAR)-based collaborations, many of which are for the Department of Defense.
Abzena
Abzena is a bioconjugate- and biologics-focused CDMO that pushes development of novel treatments forward at every stage from discovery through commercial launch. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their investments in human health. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK. #bioconjugation #linkerpayloads #ADCs #Biologics # | Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK. We provide comprehensive support for multiple modalities including: Antibodies (mAbs), FAbs, ADCs, Bispecifics, Radioconjugates, Fusion Proteins, Growth Factors, Vaccines, mRNA, Biosimilars, Peptide Oligonucleotides. Our capabilities range from: Early-Stage Research & Discovery, Design and Lead Selection, Robust Analytics, Bioassays and Immunogenicity, Antibody Engineering and Developability, Mammalian Cell Line Development, Linker Payload Design and Synthesis, Analytical Method & Formulation Development, Process Development and cGMP Manufacturing up to 2000L, Technology Transfer & Scale-Up, Regulatory Support Our extensive toolkit of services is designed to ensure our customers achieve their Target Product Profile (TPP). With early-stage research, process development and GMP manufacturing capabilities all under a single organization, we can leverage our vast capabilities and knowledge of the product, along with the requisite In Vitro and In Vivo criteria to ensure that the desired TPP can be accomplished from the project outset. | Abzena is the leading end-to-end bioconjugate (ADCs, AOCs, RDCs) and complex biologics CDMO + CRO. From discovery through commercial, we support customers with fully integrated programs or individual services that de-risk and streamline the development of new medicines. With over two decades of experience, 2000+ conjugates developed and over 200+ cell lines developed, we have the expertise and technical know-how to rapidly progress your biopharmaceutical to IND and beyond. And with footholds in the US and UK, we offer a simplified and secure supply chain. Fully integrated CDMO+CRO support across multiple modalities: Monoclonal Antibodies (mAbs), Antibody-Drug Conjugates (ADCs), Antibody-Oligonucleotide Conjugates (AOCs), Radionuclide Antibody-Conjugates (RACs) & Radionuclide Drug-Conjugates (RDCs),Bispecific Antibodies (bsAbs), Fusion Proteins, Cytokines, Recombinant & Conjugate Vaccines, Nanoparticles With Capabilities Ranging From: Early-Stage Research & Discovery, Design and Lead Selection, Robust Analytics, Bioassays and Immunogenicity, Bioconjugation & Chemistry, Antibody, Engineering and Developability, Mammalian Cell Line Development, Linker Payload Design and Synthesis, Analytical Method & Formulation Development, Process Development and cGMP Manufacturing up to 2000L, Technology Transfer & Scale-Up, Regulatory Support. Key Facts & Highlights: Over 24 years of experience developing 2000+ conjugations and 200+ cell lines. Champion Award Winner in Global Biologics at the 2025 CDMO Leadership Awards. Unique end-to-end value proposition ranging from antibody discovery to clinical-scale GMP biologic drug substance manufacture. Scientific expertise to deliver at high quality, low cost and compressed timelines. Global customer base, including most of the top 20 biopharmaceutical companies. Supply chain security with fully integrated US & UK facilities that can handle highly potent and cytotoxic molecules. 14 products utilizing Abzena’s technologies in clinical trials. Biologics discovery, design, optimization, characterization, lead selection, cell line development, process development & GMP manufacture for supply from preclinical through commercial scale. Bioconjugate (including ADCs, AOCs, RDCs) discovery, design, optimization, characterization, lead selection, cell line development, process development & GMP manufacture for supply from preclinical through commercial scale. Synthesis, analysis and GMP manufacture of APIs, payloads and highly potent compounds (HPAPI) and cytotoxic. Discovery to Phase II accelerated development for antibody-drug conjugates, including antibodies, linkers, and payloads. Tech transfer and commercial scale manufacturing up to 2000L for biologics and bioconjugates.
3PBIOVIAN
3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. Our service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production. Additionally, we provide fill and finish services for recombinant proteins and viral vectors. With a combined track record of 40 years in process development and analytical methods development, complemented by our experience in process scale-up, GMP manufacturing, and commercial supply, we are equipped to offer comprehensive manufacturing services at all stages, encompassing Drug Substance and Drug Product. Our manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland seamlessly support the diverse needs of our clients, covering pre-clinical and clinical supply to full-scale commercial manufacturing. | 3PBIOVIAN is a globally operating Contract Development and Manufacturing Organisation (CDMO), providing unparalleled end-to-end development and manufacturing services for biologics and advanced therapies. Collaboration is at the core of how we work. We partner closely with our clients, adapting to their unique needs and guiding them through every stage: from clinical development and trials to commercial production. Our client-oriented approach ensures seamless project execution and efficient progression. Our service offering spans multiple platforms, including microbial and mammalian expression systems, adenoviruses, adeno-associated viruses (AAV), cell therapy, and plasmids. With a diverse range of bioreactor sizes, we offer flexible production scaling to meet the needs of biopharmaceutical companies worldwide. Leveraging decades of expertise and extensive capabilities, we position ourselves as a leading pan-European independent biologics CDMO, dedicated to advancing therapies that address patients’ unmet clinical needs, making advanced biologics and tomorrow’s life transforming therapies. GMP certified 3PBIOVIAN offers GMP manufacturing services for microbial and mammalian protein expression platforms, viral vector production for adenoviruses and AAVs, cell therapy, and plasmid DNA production. Summary of services › Plasmid DNA production › Cell line development › GMP cell banking and Virus Seed Stock production › Process development and optimisation › Technology transfer › Analytical methods development, qualification, and validation › Scale-up and cGMP manufacturing › Formulation development › Fill and Finish › Quality Assurance (QA) and Quality Control (QC) › Drug Substance (DS) & Drug Product (DP) release GMP manufacturing capacities › Mammalian, single use bioreactors: 50L, 200L, 400L, 2000L › Microbial, stainless-steel bioreactors: 10L, 100L, 200L, 500L, 1000L › Viral Vector manufacturing: • Adherent: Up to 500 m2 • Suspension: 10L, 25L, 50L, 200L › Plasmid DNA, stainless steel bioreactors: 25L, 40L, 200L